French study finds that the vast majority of new coronary patients produce serum neutralizing antibodies

France’s Pasteur Institute issued a press release on the 26th, the Institute and the University Hospital of Strasbourg jointly formed a research team through the investigation found that even new coronary patients will produce antibodies, within weeks of infection to obtain immunity. The findings have been published online in the Archives of American Medical Papers, the bulletin said.

French study finds that the vast majority of new coronary patients produce serum neutralizing antibodies

The researchers investigated 160 medical staff at the University Hospital of Strasbourg who were infected with the neo-coronavirus and were not hospitalized with mild symptoms.

The researchers used two methods to detect samples, one as a rapid immunodiagnostic test, and the other was an S-Flow test developed by the Pasteur Institute, which uses pseudo-virus neutralizing and testing to detect the neutralizing activity of antibodies.

Preliminary results showed that the rapid immunodiagnostic test detected antibodies in 153 samples (95.6%), and the S-Flow test detected antibodies in 159 samples (99.4%). Neutralizing antibodies in samples taken 13 to 20 days, 21 days to 27 days, and 28 days to 41 days, respectively, after the onset of symptoms.

The study showed that almost all of the health care workers involved in the study had antibodies against the new coronavirus. Over time, the neutralizing activity of antibodies increases, indicating that the body’s immunity is also increasing.

“The study found that in most cases, antibodies can prevent re-infection with the new coronavirus, at least for 40 days after the onsgoing symptoms,” Olivier Schwartz and Timothy Bruel of the Pasteur Institute, who were involved in the study, said in a statement. The goal of the current study is to assess the long-term persistence of antibody responses in these health care workers and their associated capabilities. “

Samira Fifi-Cremer of the University Hospital of Strasbourg, the paper’s lead author, said the results were encouraging and could help future research and development of the new crown vaccine.